This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Asimakopoulos FA, White NJ, Nacheva E, Green AR . Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes. Blood 1994; 84: 3086–3094.
Huh J, Tiu R, Gondek LP, O'Keefe CL, Jasek M, Makishima H et al. Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis. Genes Chromosomes Cancer 2010; 49: 390–399.
Wassie E, Finke C, Gangat N, Lasho TL, Pardanani A, Hanson CA et al. A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients. Br J Haematol 2015; 169: 71–76.
Julien SG, Dubé N, Read M, Penney J, Paquet M, Han Y et al. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis. Nat Genet 2007; 39: 338–346.
Gunawardana J, Chan FC, Telenius A, Woolcock B, Kridel R, Tan KL et al. Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. Nat Genet 2014; 46: 329–335.
Dubé N, Bourdeau A, Heinonen KM, Cheng A, Loy AL, Tremblay ML . Genetic ablation of protein tyrosine phosphatase 1B accelerates lymphomagenesis of p53-null mice through the regulation of B-cell development. Cancer Res 2005; 65: 10088–10095.
Myers MP, Anderson JN, Cheng A, Tremblay ML, Horvath CM, Parisien JP et al. TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. J Biol Chem 2001; 276: 47771–47774.
Levine RL, Gilliland DG . Myeloproliferative disorders. Blood 2008; 112: 2190–2198.
Bence KK, Delibegovic M, Xue B, Gorgun CZ, Hotamisligil GS, Neel BG et al. Neuronal PTP1B regulates body weight, adiposity and leptin action. Nat Med 2006; 12: 917–924.
Kühn R, Schwenk F, Aguet M, Rajewsky K . Inducible gene targeting in mice. Science 1995; 269: 1427–1429.
Yan D, Hutchison RE, Mohi G . Critical requirement for Stat5 in a mouse model of polycythemia vera. Blood 2012; 119: 3539–3549.
Khan I, Huang Z, Wen Q, Stankiewicz MJ, Gilles L, Goldenson B et al. AKT is a therapeutic target in myeloproliferative neoplasms. Leukemia 2013; 27: 1882–1890.
Kong G, Wunderlich M, Yang D, Ranheim EA, Young KH, Wang J et al. Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm. J Clin Invest 2014; 124: 2762–2773.
Aziz A, Baxter EJ, Edwards C, Cheong CY, Ito M, Bench A et al. Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions. J Clin Invest 2013; 123: 2169–2182.
Heinrichs S, Conover LF, Bueso-Ramos CE, Kilpivaara O, Stevenson K, Neuberg D et al. MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy. Elife 2013; 2: e00825.
Acknowledgements
We thank Dr Benjamin Neel (Laura and Isaac Perlmutter Cancer Center, New York University) for providing the Ptpn1-floxed mouse and Ptpn1 cDNA construct. We also thank Dr Constance Stein (SUNY Upstate Medical University) for help with fluorescence in situ hybridization analysis. This work was supported by US National Institute of Health (NIH) Grants R21 CA187128 (to GM), R01 HL095685 (to GM), R01 HL082983 (to JPM), U54 RR019391 (to JPM) and R01 CA113972 (to JPM) and by a grant from the Leukemia and Lymphoma Society TRP 624-13 (to JPM). GM is a Scholar of the Leukemia and Lymphoma Society.
Author contributions
FJ performed research, analyzed data and wrote the manuscript; BP, TK, HM and BP collected and analyzed data; YY analyzed data; REH conducted histopathologic analysis and revised the manuscript; KKB provided study material; JPM provided clinical specimens, analyzed data and revised the manuscript; GM designed the research, analyzed data and wrote the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Jobe, F., Patel, B., Kuzmanovic, T. et al. Deletion of Ptpn1 induces myeloproliferative neoplasm. Leukemia 31, 1229–1234 (2017). https://doi.org/10.1038/leu.2017.31
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2017.31
This article is cited by
-
Protein tyrosine phosphatase 1B in metabolic diseases and drug development
Nature Reviews Endocrinology (2024)